GAMMA Investing LLC Acquires 2,901 Shares of Amgen Inc. $AMGN

GAMMA Investing LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 22.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,039 shares of the medical research company’s stock after buying an additional 2,901 shares during the quarter. GAMMA Investing LLC’s holdings in Amgen were worth $5,250,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Evelyn Partners Investment Management LLP bought a new stake in shares of Amgen in the 2nd quarter valued at about $32,000. Howard Hughes Medical Institute bought a new position in Amgen during the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC purchased a new position in Amgen in the 3rd quarter worth approximately $34,000. Saranac Partners Ltd purchased a new position in Amgen in the 3rd quarter worth approximately $37,000. Finally, AXS Investments LLC bought a new stake in Amgen in the third quarter valued at approximately $42,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 2.7%

Shares of NASDAQ:AMGN opened at $351.48 on Thursday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The firm has a market capitalization of $189.47 billion, a P/E ratio of 24.70, a P/E/G ratio of 3.58 and a beta of 0.45. The stock has a 50 day moving average price of $359.46 and a 200-day moving average price of $326.94. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AMGN shares. Jefferies Financial Group started coverage on Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective for the company. Piper Sandler upped their price target on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Royal Bank Of Canada boosted their price objective on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Finally, Mizuho upped their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average target price of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.